




## Supplementary Figures




Figures S1-S4




**Figure S1** Consensus clustering of the ICGC cohort ( $n=66$ ),  $k=6$  was selected.

**a****b**

**Figure S2** Validation on GSE28735. (a) All patients were included (n=42). (b) Patients with OS less than 36 months were included (n=38).

**a****b****c**

**Figure S3** Functional Enrichment for gbcxMRS. (a) Gene Set Enrichment analysis (GSEA) of E-MTAB-6134 cohort. (b) GSEA of ICGC cohort. (c) ssGSEA enrichment score of ferroptosis between high and low gbcxMRS groups.



**Figure S4** The drug sensitivity analysis with gbcxMRS. (a-b) There is no significant difference between gbcxMRS groups in the drug sensitivity of gemcitabine and paclitaxel. (c) The low gbcxMRS group showed the significant sensitivity of 5-fluorouracil.